SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:gup.ub.gu.se/50279"
 

Sökning: onr:"swepub:oai:gup.ub.gu.se/50279" > Efficacy, safety an...

Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure

Deedwania, P. C. (författare)
Gottlieb, S. (författare)
Ghali, J. K. (författare)
visa fler...
Waagstein, Finn, 1938 (författare)
Gothenburg University,Göteborgs universitet,Hjärt-kärlinstitutionen,Wallenberglaboratoriet,Cardiovascular Institute,Wallenberg Laboratory
Wikstrand, John, 1938 (författare)
Gothenburg University,Göteborgs universitet,Hjärt-kärlinstitutionen,Wallenberglaboratoriet,Cardiovascular Institute,Wallenberg Laboratory
visa färre...
 (creator_code:org_t)
Oxford University Press (OUP), 2004
2004
Engelska.
Ingår i: Eur Heart J. - : Oxford University Press (OUP). - 0195-668X. ; 25:15, s. 1300-9
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • AIM: To study the efficacy and tolerability of beta-blockade in elderly patients with heart failure in the MERIT-HF study. METHODS AND RESULTS: Cox proportional hazards model was used to calculate hazard ratios (HR) with 95% confidence intervals (CI). Risk reduction was defined as (1-HR). In patients > or = 65 years total mortality was reduced by 37% (95% CI 17% to 52%; p=0.0008), sudden death by 43% (95% CI 17% to 61%; p=0.0032), and death from worsening heart failure by 61% (95% CI 32% to 77%; p=0.0005). Hospitalisations for worsening heart failure was reduced by 36% (p=0.0006). Elderly patients with severe heart failure (NYHA class III/IV with ejection fraction < 0.25; n=425, and patients above 75 years (n=490) showed similar risk reductions. Metoprolol CR/XL was safe and well tolerated both during initiating therapy and during long-term follow-up. CONCLUSIONS: Metoprolol CR/XL was easily instituted, safe and well tolerated in elderly patients with systolic heart failure. The data suggest that these are the patients in whom treatment will have the greatest impact as shown by number of lives saved and number of hospitalisations avoided. The time has come to overcome the barriers that physicians perceive to beta-blocker treatment, and to provide it to the large number of elderly patients with heart failure in need of this therapy.

Nyckelord

Adrenergic beta-Antagonists/*therapeutic use
Adult
Aged
Aged
80 and over
Blood Pressure/physiology
Dose-Response Relationship
Drug
Double-Blind Method
Heart Failure
Congestive/*drug therapy/mortality/physiopathology
Heart Rate/physiology
Hospital Mortality
Humans
Metoprolol/*therapeutic use
Middle Aged
Proportional Hazards Models
Prospective Studies
Treatment Outcome

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy